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Capsular polysaccharides (CPSs) are protective structures on the surfaces of
many Gram-negative bacteria. The principal CPS of the human pathogen and
Tier 1 select agent Burkholderia pseudomallei consists of a linear repeat of
–3)-2-O-acetyl-6-deoxy--d-manno-heptopyranose-(1–. This CPS is critical to
the virulence of this emerging pathogen and represents a key target for the
development of novel therapeutics. wcbI is one of several genes in the CPS
biosynthetic cluster whose deletion leads to significant attenuation of the
pathogen; unlike most others, it has no homologues of known function and no
detectable sequence similarity to any protein with an extant structure. Here,
the crystal structure of WcbI bound to its proposed product, coenzyme A, is
reported at 1.38 Å resolution, solved using the halide-soak method with multiple
anomalous dispersion. This structure reveals that WcbI incorporates a
previously described 100-amino-acid subdomain into a novel, principally helical
fold (310 amino acids). This fold adopts a cradle-like structure, with a deep
binding pocket for CoA in the loop-rich cradle. Structural analysis and
biophysical assays suggest that WcbI functions as an acetyltransferase enzyme,
whilst biochemical tests suggest that another functional module might be
required to assist its activity in forming the mature B. pseudomallei capsule.
1. Introduction
The human pathogen Burkholderia pseudomallei is a Gram-
negative soil-dwelling bacterium that causes a severe febrile
disease, melioidosis. The organism is endemic throughout the
tropics (Wiersinga et al., 2012) and is the most common form
of community-acquired infection in parts of Thailand and
Northern Australia. It has been reported on every continent
except Antarctica (Stone, 2007). B. pseudomallei infects
humans, a range of animals and some plants. Disease states in
humans include acute and chronic forms, ranging from acute
pneumonia or septicaemia to chronic abscesses (Lazar Adler
et al., 2009); without the use of appropriate antibiotics, the
septicaemic form of melioidosis has a mortality rate that
exceeds 90% (Warner et al., 2007). Many countries in which
B. pseudomallei is endemic are located in less developed parts
of the world, where bacteria cause disease in large numbers of
people. It is believed that between 20 and 50% of all patients
diagnosed with severe forms of melioidosis will die, depending
on their access to appropriate medicines and healthcare, which
is often not sufficient in less developed countries. Even with
satisfactory healthcare, relapse of the disease is a common
problem, with many patients requiring treatment for the rest
of their lives (Lazar Adler et al., 2009). Because of its high
mortality rate, B. pseudomallei is considered as a potential
bioterror threat and is currently classed by the US Centers for
Disease Control (CDC) as a Tier 1 select agent (Department
of Health and Human Services, 2012). B. pseudomallei is
naturally resistant to many antibiotics, and has no currently
available vaccine. An effective vaccine to both protect popu-
lations exposed to infection and to alleviate the risk of
bioterrorism is thus urgent.
The principal capsular polysaccharide (CPS-I) of B. pseudo-
mallei is one of the best verified virulence factors of this
organism (Lazar Adler et al., 2009; Wiersinga et al., 2006) and
is considered to be a strong candidate for vaccine develop-
ment. Ablation of CPS-I abolishes B. pseudomallei virulence
in animal models (Reckseidler et al., 2001; Atkins, Prior, Mack,
Russell, Nelson, Prior et al., 2002), and CPS provides partial
protection when used to vaccinate mice against melioidosis
(Nelson et al., 2004). Most strains of the non-pathogenic close
relative organism B. thailandensis do not have the genes
required for CPS biosynthesis (Reckseidler et al., 2001), and
live vaccines consisting of mutants lacking a polysaccharide
capsule have been shown to provide only partial protection
against melioidosis (Atkins, Prior, Mack, Russell, Nelson,
Oyston et al., 2002; Sarkar-Tyson et al., 2009; Stevens et al.,
2004; Breitbach et al., 2008).
CPS-I of B. pseudomallei and the related Tier 1 select agent
B. mallei consists of a linear polymer of –3)-2-O-acetyl-
6-deoxy--d-manno-heptopyranose-(1– (2Ac-dDHep; Reck-
seidler et al., 2001; Heiss et al., 2012). This polysaccharide is
biosynthesized by a cluster of 24 genes found on B. pseudo-
mallei chromosome 1 (Reckseidler et al., 2001; DeShazer et al.,
2001; Holden et al., 2004). The function of the majority of
these has been proposed from bioinformatics and functional
studies (Cuccui et al., 2012). However, three genes (wcbF,
wcbG and wcbI) do not have proposed functions, and the
protein responsible for 2-O-acetylation of the capsule sugars
has not been identified (Fig. 1). wcbI has been shown to be
required for virulence (DeShazer et al., 2001; Cuccui et al.,
2007). In addition, the location of the gene in this cluster, and
the diminished capsule manufacture in its absence, suggest
that this gene is necessary for efficient CPS-I production.
BLAST searches of the sequence do not reveal any homo-
logues with predicted functions, and a series of fold-
recognition servers give only equivocal matches to known
structures.
To determine the biochemical function of WcbI, we have
therefore solved its crystal structure to 1.38 Å resolution. The
structure revealed that WcbI adopts a predominantly helical
fold: the N-terminal 100 amino acids form a ligand-binding
domain fold, with the remaining 210 amino acids adopting an
entirely novel fold. The protein
binds tightly to coenzyme A and
its derivative acetyl-CoA, with an
apparent kd of 58 mM by differ-
ential scanning fluorimetry. Our
extensive biochemical assays
failed to show acetyltransferase
activity for WcbI when incubated
with any available substrate.
Based on the structure and on
biochemical and biophysical data,
we propose that WcbI functions
as an acetyltransferase and
requires another functional
module to carry out this function.
2. Materials and methods
2.1. Protein cloning, expression
and purification
Full-length wcbI from B.
pseudomallei strain K96423 (the
genomic DNA was a gift from
R. Titball, University of Exeter)
was cloned into pNIC28-Bsa4
(Savitsky et al., 2010; a gift
from O. Gileadi, SGC Oxford).
Constructs were transformed into
Escherichia coli Rosetta (DE3)
cells (Merck) and grown in ZYM-
5052 medium (Studier, 2005)
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Figure 1
Proposed pathway for the biosynthesis of 2-O-acetyl-6-deoxy--d-manno-heptopyranose from sedoheptu-
lose 7-phosphate in B. pseudomallei (after Harmer, 2010).
supplemented with 100 mg ml1 kanamycin and 20 mg ml1
chloramphenicol. Cells were grown at 37C until the OD600
reached 0.5 and then at 20C for 16 h. The harvested cells were
resuspended in 20 mM Tris–HCl pH 8.0, 0.5 M NaCl (buffer
A) and lysed using a Soniprep 150 sonicator (MSE). The
clarified lysate was purified using a nickel–agarose column
(Bioline) or a HisTrap Crude FF column (GE Healthcare).
Briefly, the loaded protein was washed with buffer A supple-
mented with 25 mM imidazole–HCl pH 8.0 and eluted with
buffer A supplemented with 250 mM imidazole–HCl pH 8.0.
WcbI was then loaded onto a Superdex 200 16/60 HR column
(GE Healthcare) and eluted isocratically with 10 mM HEPES
pH 7.0, 0.5 M NaCl. For preparation of tag-free WcbI, purified
protein was incubated at 4C for 48 h with 1:100 TEV protease
(S219V mutant; Kapust et al., 2001; purified using methods
available at http://mcl1.ncifcrf.gov/waugh_tech/protocols/
pur_histev.pdf). The sample was then extensively loaded over
nickel–agarose to remove residual undigested WcbI and TEV.
2.2. Crystallization and structure determination
All crystals were grown using the microbatch method and
were prepared using an Oryx 6 crystallization robot (Douglas
Instruments). Crystals grew in 2.5 mg ml1 WcbI, 10%(w/v)
PEG 8000, 75 mM LiCl, 75 mM MgCl2, 0.05 M HEPES pH
7.0–8.0 at 4C. Prior to flash-cooling, crystals were soaked in
cryoprotectant solutions consisting of 22%(v/v) PEG 400,
8%(v/v) PEG 8000, 1 M NaBr, 0.05 M HEPES pH 7.0, 7.5 and
8.0 for 5 min. Co-crystallization with acetyl-CoA was achieved
by growing crystals in the same conditions, with WcbI at
2 mg ml1, supplemented with 200 mM acetyl-CoA. These
crystals were cryopreserved in the above solution without
sodium bromide. The WcbI structure was solved using the
multiple anomalous dispersion (MAD) method following the
short (<5 min) cryosoaking of a crystal with bromide ions
(Dauter et al., 2000). Diffraction data were collected from a
bromide-soaked crystal on beamline I02 at the Diamond Light
Source synchrotron at four wavelengths (Table 1) using
an ADSC detector. Data were processed with XDS (Kabsch,
2010) and scaled together using SCALA (Evans, 2011) and the
xia2 (Winter, 2010) pipeline. Most of the further data and
model manipulations were carried out using programs from
the CCP4 suite (Winn et al., 2011). Anomalous scatterers were
located and a polyalanine model of the protein was built using
the SHELXC/D/E pipeline (Sheldrick, 2010) implemented in
HKL2MAP (Pape & Schneider, 2004). A full atomic model
was built using the ARP/wARP/REFMAC5 pipeline (Langer
et al., 2008; Murshudov et al., 2011). High-resolution data were
collected from the acetyl-CoA-soaked crystal on beamline I24
at Diamond Light Source using a PILATUS detector. The
final refinement of both models was conducted with PHENIX
(Adams et al., 2010). The model was manually rebuilt in Coot
(Emsley et al., 2010) and the final model was validated using
PHENIX and MolProbity (Chen et al., 2010). The statistics of
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Table 1
Data-collection and refinement statistics.
Values in parentheses are for the outer resolution shell.
Br soak
Data set Low-energy remote Peak Inflection High-energy remote CoA complex
Beamline (Diamond Light Source) I02 I02 I02 I02 I24
Space group P1 P1 P1 P1 P1
Unit-cell parameters (Å, ) a = 47.2, b = 67.9,
c = 71.9,  = 62.9,
 = 76.2,  = 69.8
a = 47.2, b = 67.9,
c = 71.9,  = 62.9,
 = 76.2,  = 69.8
a = 47.2, b = 67.9,
c = 71.9,  = 62.9,
 = 76.2,  = 69.8
a = 47.2, b = 67.9,
c = 71.9,  = 62.9,
 = 76.2,  = 69.8
a = 46.9, b = 68.0,
c = 71.5,  = 63.0,
 = 76.5,  = 70.0
Rotation interval collected () 360 180 180 360 300
Wavelength (Å) 0.9795 0.9200 0.9202 0.9098 0.9778
Resolution range (Å) 63.7–1.56 (1.60–1.56) 63.7–1.96 (2.01–1.96) 63.7–1.86 (1.91–1.86) 63.7–2.01 (2.–2.01) 24–1.38 (1.42–1.38)
Completeness (%) 92.0 (72.6) 66.0 (12.5) 56.6 (2.1) 69.6 (16.8) 92.3 (59.4)
Redundancy 3.9 (3.7) 3.8 (3.6) 1.9 (1.5) 1.9 (1.9) 2.8 (2.5)
hI/(I)i 13.0 (2.2) 15.3 (2.0) 14.8 (2.1) 16.3 (2.4) 55.9 (5.7)
Rsym† (%) 4.8 (57.1) 4.4 (59.0) 3.2 (29.7) 5.1 (46.6) 2.4 (18.4)
Rcryst‡ (%) 17.71 11.95
Rfree (5% of total data) (%) 21.29 15.7
R.m.s.d., bond lengths§ (Å) 0.011 [0.019] 0.007 [0.020]
R.m.s.d., bond angles§ () 1.5 [2.0] 1.3 [2.0]
Wilson B factor} (Å2) 31.6 21.0
Average B factor (Å2)
Protein 27.2 19.0
Solvent 37.9 35.0
Ligand CoA 36.8 18.9
Occupancy of ligand 0.5–0.6 0.80–0.88
Ramachandran plot analysis†† (%)
Residues in most favoured regions 97.1 97.2
Residues in outlier regions 0.16 0.16
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hkl jFobsj. § Target values are given in square brackets. } The Wilson B factor was estimated by SFCHECK (Vaguine et al., 1999). †† Ramachandran plot
analysis was performed by MolProbity (Chen et al., 2010).
the refinement and the stereochemistry of the final models are
summarized in Table 1. The coordinates and structure factors
were deposited in the Protein Data Bank under accession
codes 4bqn for WcbI covalently bound to coenzyme A and
4bqo for the native structure. Figs. 2(a), 2(d), 2( f), 3(a), 3(c)
and Supporting Figs. S2(a), S2(c) and S3(a) were prepared
with the PyMOL Molecular Graphics System (Schrödinger),
and Fig. 3(b) and Supporting Figs. S2(b) and S3(b) were
prepared with LigPlot+ (Laskowski & Swindells, 2011). The
stereoview of the WcbI C backbone (Fig. 2b) was prepared
using the program BobScript (Kraulis, 1991; Esnouf, 1997) and
Fig. 2(c) was prepared with TOPS (Michalopoulos et al., 2003).
2.3. Differential scanning fluorimetry (DSF)
DSF samples were prepared at the following concentrations
in a final volume of 20 ml: 0.1 mg ml1 protein, 10 mM HEPES
pH 7.0, 150 mM NaCl, 8 SYPRO Orange dye (Invitrogen;
Niesen et al., 2007). Potential ligands were added to final
concentrations of between 0.1 mM and 1 mM. All samples
were prepared in triplicate. Fluorescence was measured using
a StepOne quantitative PCR machine (Applied Biosystems)
while heating the samples in a gradient from 25 to 99C over
40 min. Measurements were taken every 0.37C. The DSF
curves showed a mixture of two populations of protein. Rather
than calculating the midpoint temperature of the unfolding
transition (Tm), the curves were fitted to determine the
proportions of protein in the bound and unbound states. A full
description of this approach will be published shortly (Vivoli
& Harmer, in preparation). Briefly, the differential of each
DSF curve was calculated using the Protein Thermal Shift
software package (Applied Biosystems), and each curve was
compared with the unbound sample and a sample at the
highest ligand concentration to determine the proportion in a
bound state using SPSS v.20. The dissociation constant kd was
calculated using
proportion bound ¼







E0 was treated as a constant, and the value of kd was deter-
mined using SPSS v.20. Following the calculation of kd, a
standard curve was modelled using this equation. The likely
proportion bound in the highest ligand concentration sample
was calculated and a differential curve at 100% ligand
concentration was modelled. The determination process was
then repeated until the model converged. 29 concentrations of
CoA were used in at least triplicate, and the results reported
are representative of results obtained on at least three days.
2.4. Acetyltransferase kinetic assays
2.4.1. Assay of coenzyme A production by coupling to
50-dithio-bis(2-nitrobenzoic acid). The activity assay was
based on the hydrolysis of acetyl-CoA in the presence of the
substrates guanosine diphosphate mannose (GDP-mannose)
or mannotetraose. 50-Dithio-bis(2-nitrobenzoic acid) (DTNB)
was used as a colorimetric developing agent for the detection
of CoA (Shaw, 1977). Acetyl-CoA (0–1 mM), GDP-mannose
(4 mM) or mannotetraose (2 mM) and 0.5 mM purified
recombinant WcbI were mixed and pre-incubated at room
temperature for 5 min in a 96-well plate in a final volume of
50 ml containing 100 mM Tris–HCl buffer pH 8.0. The reaction
was stopped with 25 ml guanidine hydrochloride solution
(6.4 M guanidine–HCl, 0.1 M Tris–HCl pH 8.0) and incubated
for 3 min, gently shaking. Finally, 25 ml 10 mM DTNB was
added to the stopped reaction and the absorbance at 412 nm
(peak of absorbance of 2-nitro-5-thiobenzoic acid; TNB) was
measured. Rates were calculated using an extinction coeffi-
cient for TNB at 412 nm of 13 600 M1 cm1. Reactions in
which GDP-mannose, mannotetraose, acetyl-CoA or recom-
binant WcbI were omitted served as controls. The same assay
was performed using 20 U chloramphenicol acetyltransferase
(Sigma) and 2 mM chloramphenicol for a positive control.
2.4.2. Assay of coenzyme A production using fluorescence.
The assay for the determination of acetyltransferase activity
was carried out using the acetyltransferase activity kit (Enzo
Life Sciences) as per the manufacturer’s instructions. Briefly,
in a 96-well plate, 0–3 mM donor substrate (GDP-mannose)
was diluted in 1 reaction mixture. An enzyme mixture
consisting of 25 ml 1 transferase assay buffer and 25 ml
0.5 mM WcbI was added to this. The plate was covered with a
foil sealer and incubated for 5 min with constant shaking in an
orbital shaker at room temperature. 50 ml positive control
(supplied in the kit) was added to the appropriate wells. 50 ml
ice-cold isopropyl alcohol was then added to each well. Finally,
100 ml of the 1 detection solution (supplied in the kit) was
added to each well. The plate was covered with a foil sealer
and further incubated for 10 min at room temperature without
shaking. The plate was then read at 380 nm excitation and
520 nm emission wavelengths. The test was performed in
duplicate. The signal-to-noise ratio was calculated from the
relative fluorescence unit of a blank with buffer alone.
2.4.3. Assay of coenzyme A production using a coupled
reaction with pyruvate dehydrogenase. Acetyltransferase
activity was monitored continuously using a Tecan Infinite 200
microplate reader as described previously (Kim et al., 2000).
Briefly, the coenzyme A generated in a WcbI reaction was
continuously measured using a coupled system with pyruvate
dehydrogenase; the CoA-dependent oxidation of pyruvate is
accompained by the reduction of NAD+ to NADH, which was
measured spectrophotometrically at 340 nm. Reactions were
performed in 50 ml and consisted of 10 mM HEPES pH 7,
0.2 mM NAD+, 0.2 mM thiamine pyrophosphate, 5 mM
MgCl2, 1 mM dithiothreitol, 2.5 mM pyruvate and 0.03 U
pyruvate dehydrogenase (Sigma–Aldrich), 1 mM GDP-
mannose or 1 mM mannotetraose, 0.5 mM recombinant WcbI
and 0–500 mM acetyl-CoA. Assays were performed in dupli-
cate at 37C, mixing all reagents without WcbI for 3 min to
exhaust endogenous CoA; after this, WcbI was added and the
reaction was followed for a further 5 min. The same assay was
performed using 20 U chloramphenicol acetyltransferase
(Sigma) and 1 mM chloramphenicol as a positive control.
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3. Results
3.1. Phasing
The crystal structure of WcbI was determined by the
multiple-wavelength anomalous dispersion method, using data
collected at four wavelengths. Peak, inflection and high-energy
remote data were collected to a limited resolution with short
exposures and low transmission in order to minimize possible
radiation damage and to collect multiple equivalents. As the
WcbI crystals belonged to space group P1, a high-energy
remote data set was collected over a rotation interval of 360
to increase the data redundancy. No radiation damage to the
crystal was apparent after the first three data sets, so the
exposure times were increased for the low-energy remote data
set, which was collected over an interval of 360 to a high
resolution of 1.56 Å. As the crystal proved to be stable to
X-rays and diffracted well, the reflections from corners of the
detector were used in anomalous phasing, as the experiment
geometry was the same for the different data sets. In spite of
the low reported completeness of the peak, inflection and
high-energy remote sets (Table 1), these data were over 90%
complete to 2.7 Å resolution. The coordinates of 24 Br ions
were used for phasing. These were located using 1000 attempts
by SHELXD at 2.4 Å resolution with a correlation of 27.3%
(20.5% at high resolution). The high resolution of the low-
energy remote data set was crucial for subsequent density
modification and successful building of the WcbI polyalanine
model (605 residues out of 622) by SHELXE. For the correct
hand, the correlation for the partial structure against the
native data was 36.5%.1 The full WcbI atomic model was built
by ARP/wARP using the polyalanine model produced by
SHELXE and the low-energy remote data. This was found to
contain bound CoA, carried through purification from the
expression host, and will henceforth be termed the WcbI
native structure. A second crystal was obtained co-crystallized
with substrate acetyl-CoA, and high-resolution complex data
were collected. The statistics of data collection and of model
refinement and validation are presented in Table 1.
3.2. Quality of the models
The structure of the CoA complex of WcbI and the native
structure were refined by PHENIX and CCP4, respectively, to
resolutions of 1.38 and 1.56 Å, respectively. For each model
the final round of refinement resulted in acceptable values of
the R factor and Rfree. The WcbI crystals contained two
independent molecules in the unit cell. Some residues were
not modelled owing to poor electron density at the N-termini.
The G-factors calculated for both models confirmed that the
structures have normal stereochemical properties as given by
PROCHECK (Laskowski et al., 1993). The Ramachandran
plots of the models (Chen et al., 2010) revealed that at least
97% of the residues lie in the most favoured regions. The
native structure contains 38 bromide ions. These were located
using anomalous difference synthesis with peak Br data and
phases from the refined model. Cofactor molecules were
positioned in the active site using Fo Fc OMIT maps and the
occupancies of these molecules and the bromides were refined
by PHENIX. In both subunits of both structures Ile244 is the
sole Ramachandran plot outlier. This residue is well defined in
the electron density and the B factors of its atoms are low.
Many residues were modelled with alternative conformations
of their side chains. For several regions in both structures the
main chain was modelled in an alternative conformation.
There are no WcbI residues with a cis conformation.
3.3. Overall structure
The triclinic unit cell of the WcbI crystal contains two
molecules (residues 2–310 for chain A and residues 4–310 for
chain B). Comparison of the structure with extant structures
using the protein structure comparison services DALI
(http://ekhidna.biocenter.helsinki.fi/dali_server/; Holm &
Rosenström, 2010) and PDBeFold (http://www.ebi.ac.uk/
msd-srv/ssm; Krissinel & Henrick, 2004) revealed that WcbI
largely adopts a novel fold. The fold consists of two sub-
domains (Figs. 2a, 2b and 2c). The N-terminal lobe (amino
acids 2–102) forms a four-stranded parallel -sheet with
connectivity 1x, +2x, +1x (Richardson, 1981) flanked on one
side by two -helices (1–2) and on the other by three -
helices (3–5). This arrangement has previously been
observed in a number of proteins with different functions, for
example Neisseria meningitidis glycerate kinase (New York
SGX Center for Structural Genomics, unpublished work; PDB
entry 1to6) and the zinc-transport protein ZnuA (Banerjee et
al., 2003; PDB entry 1pq4). Most of these proteins have a
ligand/metal-binding site in the crevice formed at the C-
termini of 1 and 3 of the -sheet. Cys14 of WcbI is located
in this position. The C-terminal subdomain (amino acids 103–
311) is a novel arrangement of several -helices that pack
against the N-terminal domain (Fig. 2a). Analytical size-
exclusion chromatography (Supporting Fig. S1) indicates that
WcbI is likely to be monomeric in solution. The two molecules
are related by an approximate twofold axis with a rotation
angle of 175; however, the buried surface area at the interface
is only 140 Å2, which is less than 4% of the total accessible
monomer surface area. Analysis of the structure with PISA
did not indicate any likely multimerization interfaces
preserved in the crystal.
3.4. Binding of acetyl-CoA and CoA to WcbI
Analysis of early crystals of WcbI revealed that an
unidentified ligand had been partially retained with the
protein from expression in E. coli through the purification
process (Supporting Fig. S2a). Mass spectrometry clearly
identified CoA as the ligand co-purified with WcbI (data not
shown). We therefore co-crystallized WcbI with acetyl-CoA.
CoA was clearly defined in the electron-density map (Fig. 3a)
in both protomers, whilst acetyl-CoA was only observed in
protomer A. However, following occupancy refinement, the
occupancy of the acetyl moiety was too low for meaningful
modelling. The molecule is located in a funnel-shaped cleft,
surrounded by loops. The bound cofactor adopts a U-like
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1 Correlations of over 30% at this stage generally indicate a correct solution.
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Figure 2
The structure of WcbI reveals a novel fold. (a) Cartoon representation of the crystal structure of WcbI in two orientations. Termini and secondary-
structure elements are labelled. For the N-terminal subdomain -helices and loops are shown in red and -sheets in yellow; for the C-terminal subdomain
-helices and loops are shown in blue and -sheets in green. (b) Stereoview of the C backbone in the same orientation as in the left-hand image of (a).
Every tenth residue is numbered. (c) Topological diagram of the polypeptide fold with -helices indicated by circles and -strands by triangles coloured
as in (a). (d) Cartoon representation of WcbI in the orientations in (a) coloured as a rainbow with the N-terminus in blue and the C-terminus in red. (e)
Schematic diagram of the fold of WcbI. -Helices and 310-helices are shown as cylinders and -sheets are shown as arrows. Secondary-structure elements
are coloured as in (d). The start and end residue of each element is indicated. (f) Cartoon representation of the novel fold C-terminal subdomain
coloured as a rainbow with the N-terminus in blue and the C-terminus in red. The substrate coenzyme A is shown as spheres. Carbon, cyan; oxygen, red;
nitrogen, blue; sulfur, yellow; phosphorus, orange. Interacting residues from the novel subdomain are shown as lines. The secondary-structure
assignments in all panels were made according to TOPS (Michalopoulos et al., 2003). (a), (b), (d) and (f) were prepared with the PyMOL Molecular
Graphics System (Schrödinger) and (c) was prepared with TOPS.
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Figure 3
WcbI binds to coenzyme A. (a) Electron-density map showing the binding of coenzyme A (CoA) to WcbI. WcbI is shown as a cyan cartoon, with CoA as
sticks. For clarity, water molecules are not shown. An Fo Fc OMIT map is shown contoured at 3. The bond from CoA to Cys14 is shown. (b) Schematic
drawing of the WcbI–CoA interactions. (c) Key WcbI–CoA interactions. WcbI is shown as a cyan cartoon, with interacting side chains as purple sticks.
CoA is shown as sticks. Hydrogen-bond distances are shown. Nitrogen, blue; oxygen, red, phosphorus, orange; CoA carbon, yellow; WcbI carbon, purple.
(a) and (c) were prepared with the PyMOL Molecular Graphics System (Schrödinger) and (b) was prepared with LigPlot+ (Laskowski & Swindells,
2011).
overall conformation that is stabilized by several hydrogen
bonds to WcbI, electrostatic interactions with charged resi-
dues, and hydrophobic contacts (Fig. 3b, Supporting Fig. S2b).
In both protomers, the -mercaptoethylamine group of CoA
forms a disulfide bond to the residue Cys14 (Figs. 3b and 3c),
whilst the acetyl-CoA S atom is positioned near, but slightly
away, from this and its carbonyl group is hydrogen-bonded to
the S atom of Cys14 and His201 (data not shown). Interest-
ingly, in the native structure the CoA terminal SH group
points away from Cys14 toward Cys41 (Supporting Fig. S2a),
perhaps owing to a more reducing environment of the crys-
tallization conditions. Water molecules and Tyr97 form
hydrogen bonds to the 4-phosphopantothenic acid portion of
the acetyl-CoA (Fig. 3c, Supporting Fig. S2c). The side chain
of Arg294 is in electrostatic contact with the 30-phosphate
group; the amide N atoms of Ser69, Arg167 and Asn172 form
hydrogen bonds to the 50-phosphate group. Finally, water
molecules form hydrogen bonds to the ADP moiety, which is
also involved in a cation– interaction with the guanidinium
group of Arg167 (Fig. 3c, Supporting Fig. S2c). The extensive
interactions of CoA with both the N-terminal and C-terminal
domains is in contrast to the GNAT acetyltransferases that
superficially resemble the N-terminal domain of WcbI, in
which CoA is intimately bound to a single domain (Supporting
Fig. S3).
3.5. Ligand- and cofactor-binding study by differential
scanning fluorimetry
To verify that CoA is a genuine ligand for WcbI, we
investigated its binding using differential scanning fluorimetry
(DSF; Niesen et al., 2007). Firstly, the protein was extensively
dialysed in the presence of reducing agents to remove any
disulfide-bonded CoA from the protein. The apoprotein was
then incubated with a range of CoA concentrations and the
thermal stability of the protein was probed. The presence of
CoA showed a marked stabilizing effect, raising the apparent
melting temperature by 10C (Fig. 4a), whilst a range of other
common chemicals found in bacteria (after Niesen et al., 2007)
failed to give any significant change (data not shown). Fitting
of the data (Fig. 4b) indicated a dissociation constant kd of 58
 2 mM, which is well within the normal range of bacterial
acetyl-CoA concentrations (Takamura & Nomura, 1988).
As wcbI is essential for the virulence of B. pseudomallei
(Cuccui et al., 2007), and the activity to acetylate the CPS has
not been identified (Cuccui et al., 2012), we hypothesized that
WcbI might be this acetylase. To this end, using DSF, we
investigated whether WcbI might bind to any potential
substrates. We tried a range of simple sugars (d-mannose,
d-maltose, d-lactose, d-arabinose and d-lyxose), sugar poly-
mers (cellubiose and polymannose) and nucleotides and sugar
nucleotides (GDP, UDP and GDP-mannose). In each case
there was no apparent alteration in the melting temperature
(Table 2). It was apparent that it would not be possible to
identify a potential substrate in this manner.
3.6. Acetyltransferase kinetic assays
To determine whether enzymatic assays could assist in
determining a potential substrate for WcbI, we used several
different assays to assess the capacity of the enzyme to
acetylate GDP-mannose or mannotetraose. These were
selected as excellent analogues for the most likely substrates
for WcbI: GDP-mannose is highly similar to GDP-6-deoxy--
d-manno-heptopyranose, differing by one –CH2– group; whilst
mannotetraose is a reasonable analogue of the polymerized
sugar (having similar sugar units but a slightly different
linkage). We attempted three chemically different assays for
acetyltransferase activity. A DTNB-based assay (Riddles et al.,
1983), which measures the level of free thiols (and hence spent
CoA), was performed. No significant acetylase activity was
detected using GDP-mannose or mannotetraose as acceptor
substrates. Whilst small changes in the product absorbance
were observed, these were comparable to those seen in a
bovine serum albumin negative control. Indeed, the back-
ground reaction rate increased with increasing acetyl-CoA or
recombinant WcbI concentrations. WcbI carries over some
CoA from purification, apparently forming a covalent thiol
adduct with Cys14, as the crystal structures attest (Fig. 3a).
Similar adducts resulted in a catalytically inactive form in
the case of glucosamine-6-phosphate N-acetyltransferase 1
(Dorfmueller et al., 2012). This enzyme can be reactivated
under reducing conditions with increasing amounts of redu-
cing agents. To ascertain whether addition of reducing agents
could rescue WcbI activity, we repeated this assay in the
presence of DTT. Although there was a greater increase in the
absorbance at 412 nm, this was also observed in controls and is
likely to arise from the seven free cysteines of WcbI and the
free CoA contaminant reacting with the DNTB molecule,
suggesting that this assay is not suitable for this purpose.
However, as expected, in the positive control performed using
chloramphenicol acetyltransferase (CAT) the assay clearly
shows a significant amount of CAT enzyme activity compared
with WcbI (Fig. 5a).
We therefore performed a second assay, specifically
measuring free CoA using a fluorescent detection kit. Using a
concentration range of GDP-mannose from 0 to 3 mM and
constant WcbI and acetyl-CoA, there was no evidence for the
transfer of the acetyl group to the substrate GDP-mannose
compared with a control reaction (Fig. 5b). A third, coupled
assay was therefore performed. In this assay, spent CoA is
turned over by pyruvate dehydrogenase, with concomitant
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Figure 4
Biophysical characterization of WcbI binding to CoA. (a) Differential
scanning fluorimetry thermal denaturation curves for WcbI show a
biphasic response. With no CoA (black line) or a high saturation (1 mM)
of CoA (grey line), a monophasic response is observed. At intermediate
concentrations of CoA (60 mM; dashed black line), a biphasic curve
representing some bound and some unbound WcbI is observed. (b) WcbI
shows dose-dependent binding to CoA, as expected for a single tight-
binding molecule. All experiments were performed in triplicate and the
data are representative of at least three experiments. The black line
represents the fit of the data according to (1).
Table 2
Thermodynamic analysis of the binding of sugars, sugar nucleotides and
CoA to WcbI by DSF experiments.
Ligands (1 mM) Tm  SD† (
C)
No ligand 37.4  0.4
CoA 46.2  0.2
Acetyl-CoA 45.6  0.5
d-Mannose 37.0  0.1
d-Maltose 37.1  0.1
d-Lactose 37.5  0.3
d-Arabinose 37.0  0.1
d-Lyxose 37.1  0.1
Cellubiose 37.7  0.2
Polymannose 36.2  0.1
GDP 37.0  0.1
UDP 36.9  0.05
GDP-mannose 38.2  1.0
† The melting temperature Tm is expressed as the mean  SD and was determined in
triplicate. The concentration of WcbI was 0.11 mg ml1.
reduction of NAD+ to NADH. This reaction can be followed
spectrophotometrically at 340 nm in real time. The assay
performed well in the presence of a test acetyltransferase
(chloramphenicol acetyltransferase). However, using WcbI,
no activity was observed using acetyl-CoA and either GDP-
mannose or mannotetraose as substrates (Fig. 5c). Further-
more, computational approaches based on analysis of protein
sequence and structure, such as the 3DLigandSite (Wass et al.,
2010), LIGSITE csc (Huang & Schroeder, 2006), ConCavity
(Capra et al., 2009) or FINDSITE (Brylinski & Skolnick, 2008)
servers, have been employed to predict potential further
protein functional sites, including ligand-binding sites. All of
these prediction servers confirmed the presence of a binding
pocket for CoA, but did not identify any WcbI surface region
suitable for interactions with sugars or sugar-nucleotides.
4. Discussion
The B. pseudomallei capsular polysaccharide consists of a
linear repeat of –3)-2-O-acetyl-6-deoxy--d-manno-hepto-
pyranose-(1–. The genes required for the biosynthesis of this
polysaccharide have been mapped in B. pseudomallei (Reck-
seidler et al., 2001) and B. mallei (DeShazer et al., 2001). Six
genes (wcbJ, wcbK, wcbL, gmhA, wcbM and wcbN) form a
unit that is proposed to synthesize the precursor sugar GDP-6-
deoxy--d-manno-heptopyranose (dDHep) from sedoheptu-
lose 7-phosphate, a pentose phosphate pathway intermediate
(Cuccui et al., 2012; Fig. 1). Nevertheless, the protein(s) that
acetylates either GDP-6-deoxy-heptose or the partially poly-
merized capsule has not been identified. To date, WcbI has no
predicted function (DeShazer et al., 2001; Reckseidler et al.,
2001), but has been shown to be required for virulence
(Cuccui et al., 2007) and for the production of the capsule
immunogen (Cuccui et al., 2012).
The crystal structure of WcbI demonstrated that this
protein largely adopts a novel fold (Fig. 2). The fold of the
N-terminal domain (amino acids 2–102) is common to several
extant protein structures involved in signalling, ligand binding
and nucleotide chemistry. The remaining 208 amino acids form
an extended, largely -helical structure, although a short
portion also packs onto the N-terminal domain. It is striking
that this fold generates a helical backbone that presents a
loop-rich region at the interface between this domain and the
N-terminal domain. The outcome is a large cleft between the
two domains, with the promise of molecular flexibility to aid
the ingress and egress of substrates, and perhaps to allow some
remodelling of the binding site.
Surprisingly, our crystal structure of WcbI showed that the
protein carries a ligand molecule through purification from
E. coli (Supporting Fig. S2). Differential scanning fluorimetry
demonstrates that this molecule is likely to be coenzyme A, as
the presence of this molecule increases the apparent melting
temperature of WcbI by approximately 10C (Table 2, Fig. 4a).
The apparent kd of 58 mM is well within the physiological
range for most bacteria, implying that this is a reasonable
candidate for the substrate of the protein. Co-crystallization
with 200 mM acetyl-CoA led to almost complete occupancy of
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Figure 5
WcbI shows no detectable acetyltransferase activity. (a) Acetyltrans-
ferase activity was measured using the DTNB assay. Each column
represents an average of three measurements. The concentrations of
acetyl-CoA and GDP-mannose were held constant at 1 and 4 mM,
respectively. The same assay performed with chloramphenicol acetyl-
transferase and 2 mM chloramphenicol served as a positive control.
Reactions in which recombinant WcbI and CAT were omitted served as a
negative control. (b) Acetyltransferase activity was measured using a
fluorescence-based activity assay. Concentrations of GDP-mannose
ranging from 0 to 3 mM were used, with the WcbI concentration held
constant. The positive control supplied in the kit was used according to the
manufacturer’s instructions. (c) Acetyltransferase activity was measured
using a coupled assay with pyruvate dehydrogenase. Substrate concen-
trations were 0.5 mM for acetyl-CoA and 1 mM for GDP-mannose. The
same assay was performed using CAT and 1 mM chloramphenicol as a
positive control. A negative control was performed without either
enzyme. The rates were calculated using the extinction coefficient for
NADH. All columns represent the average  standard deviation of two
measurements.
the ligand, with all CoA ligand atoms visible in the density.
Although there is low occupancy of the acetyl group in the
structure, the functional groups of acetyl-CoA form an
extensive set of interactions with the protein, supporting the
premise that this is a bona fide ligand of WcbI. It is therefore
not unreasonable to hypothesize that WcbI could provide
the missing acetyltransferase activity. A structural similarity
search did not yield matches with other known acetyl-
transferases; the highest scoring PDBeFold hit (Q = 0.15; PDB
entry 4h08, a putative hydrolase; Joint Center for Structural
Genomics, unpublished work) and DALI hit (Z = 9.8; PDB
entry 3hg7, a putative dehydrogenase; New York SGX
Research Center for Structural Genomics, unpublished work)
have three helices in a similar conformation but otherwise
have no similar structure. Comparison with previously
described GNAT acetyltransferases demonstrated that WcbI
folds and binds CoA in a very different manner (Supporting
Fig. S3).
To pursue this hypothesis, we performed kinetic and
biophysical assays. In contrast to the results observed with
CoA (Fig. 4a), no thermal shifts were observed in the presence
of potential substrates such as simple sugars (d-mannose,
d-maltose, d-lactose, d-arabinose and d-lyxose), sugar poly-
mers (cellubiose and polymannose) or nucleotides or sugar
nucleotides (GDP, UDP and GDP-mannose; Table 2). This
was the case either in the presence or in the absence of acetyl-
CoA, indicating that the binding of the first substrate does not
create a site for a secondary substrate. These data do not
unequivocally eliminate the possibility of a second substrate
binding: there are cases in which a ligand may bind tightly
without shifting the melting temperature of a protein, and
larger Tm shifts are observed for more entropically driven
compound binding (Vedadi et al., 2010).
Given the quite clear binding of CoA to a protein required
for capsule biosynthesis, the need for an acetyltransferase in
the biosynthetic pathway and the suggestive conformation of
the bound CoA, a detailed kinetic analysis was performed. We
used three different biochemical assays to demonstrate the
acetyltransferase activity of WcbI. None of these showed any
detectable activity (Fig. 5). Assays were carried out under
both oxidizing and reducing conditions, as previous studies on
other acetyltransferases (Dorfmueller et al., 2012) have shown
that the formation of an oxidized adduct between Cys and
CoA has an inhibitory effect on catalysis, which can be re-
activated through reduction. No activity was apparent in
either environment. This was somewhat surprising, as the
structure shows CoA protruding into a funnel-shaped cavity
(Supporting Fig. S4). Furthermore, the acetyl moiety is held
in place through hydrogen bonds to Cys14 and His201,
constraining its conformation and presenting the acetyl group
in a suitable orientation for reaction.
Moreover, detailed analysis of the structure suggests that
there is no available binding site for a reacting molecule.
Analysis of the structure using four different servers suggested
that the only likely binding site for a small molecule is that
occupied by CoA. This is consistent with our observation that
likely binding partners, and a range of common cellular
chemicals, do not show any affinity for WcbI in DSF experi-
ments. These observations, coupled with the lack of any
distinguishable acetyltransferase activity, suggest that WcbI
might form part of a more extensive enzymatic complex. We
therefore propose a model in which WcbI functions together
with a binding partner that presents the acceptor substrate.
The nature of the CoA-binding pocket, as a loop-rich cradle in
between two structured domains (Supporting Fig. S4), makes
it more amenable to the likely subtle rearrangements that
would be required to accommodate a presented ligand. In this
model, we speculate that the complex between WcbI and its
partner would transform the novel structure of WcbI into a
catalytically active form upon association. Such modularity
has been proposed as an ancestral trait providing robustness
against mutation and chemical attack (Hartwell et al., 1999),
and promoting evolvability (useful for CPS formation and
evolution in B. pseudomallei).
Our current investigations are aimed at identifying the
identity of potential partners and understanding fully how this
protein contributes to the virulence of B. pseudomallei.
5. Conclusions
The B. pseudomallei protein WcbI, which is essential for the
virulence of this organism, demonstrates an intriguing novel
fold. This fold incorporates a previously observed subdomain
into a larger folding unit, creating a loop-rich cradle-like
structure. This cradle forms a strong binding site for coenzyme
A, providing tight interactions for most of the cofactor. The
two structures of WcbI presented here, obtained under
different conditions, suggest that WcbI allows some flexibility
in the CoA head group. Soaks with acetyl-CoA reveal that the
CoA head, and likely the acetyl group, are held between
cysteine and histidine side chains from opposite sides of the
cradle in a conformation suggestive for reaction. However,
extensive experiments on WcbI have failed to demonstrate
either physical interaction with, or acetyltransferase activity
on, available substrate analogues. We therefore propose that
WcbI forms a module of a larger complex achieving the
biosynthesis of the B. pseudomallei capsular polysaccharide.
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